Bliss GVS Pharma Limited (BOM:506197)
India · Delayed Price · Currency is INR 519.50
-4.55 (-0.87%)
At close: Aug 17, 2026
Bliss GVS Pharma Revenue
Bliss GVS Pharma had revenue of 2.86B INR in the quarter ending June 30, 2026, with 37.65% growth. This brings the company's revenue in the last twelve months to 10.05B, up 20.59% year-over-year. In the fiscal year ending March 31, 2026, Bliss GVS Pharma had annual revenue of 9.27B with 14.50% growth.
Revenue (ttm)
10.05B
Revenue Growth
+20.59%
P/S Ratio
5.49
Revenue / Employee
9.73M
Employees
1,033
Market Cap
55.19B
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Mar 31, 2026 | 9.27B | 1.17B | 14.50% |
| Mar 31, 2025 | 8.10B | 394.81M | 5.13% |
| Mar 31, 2024 | 7.70B | 186.57M | 2.48% |
| Mar 31, 2023 | 7.52B | 41.33M | 0.55% |
| Mar 31, 2022 | 7.47B | 1.70B | 29.50% |
| Mar 31, 2021 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Viyash Scientific | 35.75B |
| Unichem Laboratories | 23.17B |
| FDC Limited | 21.90B |
| Morepen Laboratories | 19.51B |
| Sanofi India | 18.05B |
| Hikal | 17.35B |
| Procter & Gamble Health | 14.33B |
| Gufic Biosciences | 9.81B |
Bliss GVS Pharma News
- 5 days ago - Bliss GVS Pharma Quarterly report: Q1 2027 - Filings
- 6 weeks ago - Bliss GVS Pharma appoints Rahul Adakmol as CEO effective July 15, 2026 - Business Upturn
- 7 weeks ago - Bliss GVS Pharma announces book closure and record date for dividend payment - Business Upturn
- 2 months ago - Bliss GVS Pharma announces Re. 1 final dividend per share for FY 2025-2026 - Business Upturn
- 2 months ago - Anupam Rasayan makes Rs 299 per share open offer for Bliss GVS Pharma - Business Upturn
- 2 months ago - Bliss GVS Pharma faces Rs 299 per share open offer from Anupam Rasayan - Business Upturn
- 2 months ago - Bliss GVS Pharma achieves WHO-GMP compliance for manufacturing facility - Business Upturn
- 2 months ago - Why are Bliss GVS Pharma shares rallying over 15% today? Explained - Business Upturn